About the Editors
George P. Patrinos, University of Patras, Greece
George P. Patrinos is Professor of Pharmacogenomics and Pharmaceutical Biotechnology in the University of Patras (Greece), Department of Pharmacy and holds adjunct Professorships at Erasmus MC, Faculty of Medicine, Rotterdam (the Netherlands) and the United Arab Emirates University, College of Medicine, Department of Pathology, Al-Ain (UAE). Also, since 2010, he is Full Member and Greece’s National representative in the CHMP Pharmacogenomics Working Party of the European Medicines Agency (EMA, Amsterdam, the Netherlands) and Co-Chair of the Global Genomic Medicine Collaborative (G2MC)
George is currently Head of the Laboratory of Pharmacogenomics and Individualized Medicine, the first officially established academic laboratory on pharmacogenomics in Greece. His group consists of more than 35 staff members from graduate students to post-doctoral scientists, covering disciplines from wet and dry lab and public health genomics projects, all focusing on pharmacogenomics and personalized medicine. In particular, his research interests involve discovery work and clinical implementation of pharmacogenomics, focusing in particular in psychiatry but also cardiology and oncology, genomics of rare disorders and transcriptional regulation of human fetal globin genes. Moreover, George’s group is internationally recognized for its involvement in developing National/Ethnic Genetic databases to document the genetic heterogeneity in different populations worldwide and of genome informatics tools to translate genomic information into a clinically meaningful format. Also, George’s group has a keen interest in public health genomics to critically assess the impact of genomics to society and public health.
George has more than 250 publications in peer-reviewed scientific journals, some of them in leading scientific journals, such as Nature Genetics, Nature Rev Genet, Nucleic Acids Res, Genes Dev. Also, he has co-edited the textbook “Molecular Diagnostics”, published by Academic Press, now in its 3rd edition, and several other international textbooks, while he is the editor of “Translational and Applied Genomics” book series. Furthermore, he serves as Associate Editor and member of the editorial board of several scientific journals, such as Human Mutation, Human Genetics, Human Genomics, Pharmacogenomics, etc and has been a member of several international boards and advisory and evaluation committees.
Apart from that, George is the main co-organizer of the Golden Helix Conferences, an international meeting series on Pharmacogenomics and Genomic Medicine.
Magnus Ingelman-Sundberg, Karolinska Institutet, Sweden
Magnus Ingelman-Sundberg, PhD; BSc.Med is Professor of Molecular Toxicology and research group leader in Pharmacogenetics at the Department of Physiology and Pharmacology, Karolinska Institutet, Biomedicum since 2006. He has more than 460 original papers, (http://www.ncbi.nlm.nih.gov/pubmed/?term=ingelman-sundberg+m 31,618 citations (ISI), 47,000 in Google Scholar and an h-factor of 90 (ISI) or 115 (Google Scholar) and assigned “Highly Cited Researcher” for 2014, 2015, 2016 and 2017 by Thomson & Reuters/Clarivate. He holds an ERC Advanced Grant (AdG) for 2017-2022. He was a member of The Nobel Assembly at Karolinska Institutet 2008-2018 and a member of Editorial Advisory Boards of e.g. Trends in Pharmacological Sciences (Edit Board), Pharmacogenetics and Genomics, Pharmacogenomics, Drug Metabolism Reviews, Drug Metabolism and Disposition, Human Genomics. He has received numerous Awards, most recently the 2018 BCPT Nordic Prize in Basic and Clinical Pharmacology and Toxicology. His research focuses on genetics, polymorphism, regulation, function and toxicology of the hepatic ADME system with aims at understanding interindividual differences in drug response. Furthermore he develops novel hepatic in vitro systems for studying liver function, liver diseases and validation of hepatic drug targets. Further info from an Interview with Magnus Ingelman-Sundberg See: Trends Pharmacol Sci. 2015; 36:65-7.
Daniel J. Mueller, University of Toronto, Canada
Dr. Mueller research goals are to investigate the genomics of response and side effects to psychiatric medications, including polygenic risk scores and machine learning strategies. This line of research aims to significantly improve treatment of psychiatric conditions and to lessen the burden of medication side effects. In addition, he is actively involved in developing implementation models and developing pharmacogenetic guidelines for physicians and patients through his collaboration with international collaborators such as the Clinical Pharmacogenetics Implementation Consortium.
Munir Pirmohamed, University of Liverpool, UK
Professor Sir Munir Pirmohamed (MB ChB, PhD, FRCPE, FRCP, FBPhS, FMedSci) is David Weatherall Chair in Medicine at the University of Liverpool, and a Consultant Physician at the Royal Liverpool University Hospital. He is Director of the MRC Centre for Drug Safety Sciences, and Director of the Wolfson Centre for Personalised Medicine. He is also Director of HDR North. He is an inaugural NIHR Senior Investigator, Fellow of the Academy of Medical Sciences in the UK, Commissioner on Human Medicines and is a non-executive director of NHS England, and has been appointed as President of British Pharmacological Society. He was awarded a Knights Bachelor in the Queen’s Birthday Honours in 2015. His research focuses on personalised medicine, clinical pharmacology and drug safety.
Guilherme Suarez-Kurtz, Instituto Nacional de Câncer, Brazil
Guilherme Suarez-Kurtz is the Head of Pharmacology at the Brazilian National Cancer Institute and the Coordinator of the Brazilian National Pharmacogenetics Network. A pioneer of pharmacogenetic studies in the Brazilian population, his research explores the impact of genetic admixture on the conceptual development and the praxis of pharmacogenomics. He is a Full Member of the Brazilian Academy of Sciences, Senior Investigator of the Brazilian National Research Council and Professor of Clinical and Basic Pharmacology at Universidade do Brasil, in Rio de Janeiro, from which he received his M.D. and Ph.D. degrees. Prof. Suarez-Kurtz did postgraduate work at Faculté de Médecine de Paris, Columbia University New York and University College London. He is the editor of Pharmacogenomics in Admixed Populations, published by Landes Bioscience, a collection of essays on various aspects of pharmacogenomics from peoples of four continents. He held the Chair of the Pharmacogenetics and Pharmacogenomics Section (2014-2018), and is presently a Councillor of the International Union of Basic and Clinical Pharmacology (IUPHAR).
Jesse Swen, Leiden University Medical Center, The Netherlands
Jesse Swen PharmD, PhD is an associate professor of pharmacogenetics and clinical pharmacist-clinical pharmacologist at the Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center. He is the chair of the laboratory of the hospital pharmacy.
The long-term central goal of his career is to improve the outcomes of drug treatment by conducting first class biomedical research. To accomplish this goal he has built a research program that aims to improve drug treatment by discovery of novel pharmacogenetic biomarkers and subsequent translation to clinical practice, thereby providing a cornerstone for precision medicine. This work is seamlessly integrated with his work as chair of the pharmacy laboratory.
He has (co-)authored more than 100 (Web of Science indexed) articles in international peer reviewed scientific journals and several chapters in books. Dr. Swen is one of the primary investigators of the “Ubiquitous Pharmacogenomics” project (www.upgx.eu). U-PGx aims to implement pharmacogenetics across 7 European sites by genotyping 8,100 patients. In addition he is an active member of the Dutch Pharmacogenetics Working Group and the US Clinical Pharmacogenetics Implementation Consortium.
Recently he started a novel fundamental research line focusing on elucidating the frequently observed mismatch between the genotype and the capacity of an individual to metabolize drugs (phenotype). This phenomenon is called phenoconversion and presents a significant problem for the clinical implementation of pharmacogenetics. Underlying mechanisms involve both drug-drug interactions as well as disease state. In 2019 he was recognized as a Highly Cited Researcher by Clarivate Analytics.